AlphAIalphai — Financial news for AI agents
quiverquant.comAUG 73 min read$VIVS

VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More

VIVOSIM LABS (VIVS) is set to report Q1 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts expect revenue of $47.94 million and EPS of -$0.19. The article also cites recent institutional activity, including adds by Geode Capital and Goldman Sachs and reductions by Citadel and Two Sigma.

Original reporting
quiverquant.com
Published Aug 7, 2026, 9:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 9:37 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More — source image
Source · quiverquant.com
Decision brief

The 30-second read

$VIVSNeutralMed
01

Why it matters

Traders can use the consensus revenue and EPS expectations to frame scenarios for the Aug 10 print, but the article does not add new fundamental information beyond what is typically known for an earnings calendar item.

02

Market read

Primary value is timing and consensus framing for an upcoming earnings event; secondary value is institutional add/decrease context from recent quarters.

03

What to watch

The article does not discuss balance sheet liquidity, cash burn, guidance history, or any upcoming trial/regulatory milestones that could dominate the earnings reaction.

Relevance 5/10Novelty 4/10Timing: Ahead of Aug 10 pre-market earnings release

Background

The piece is an earnings preview for VIVOSIM LABS, citing an expected Aug 10 pre-market release and consensus estimates, alongside institutional holdings changes.

Company-level read

Ticker impact

$VIVSNeutralMedium confidence
Context

VIVOSIM LABS is set to report Q1 2026 earnings Aug 10 pre-market, with consensus revenue of $47.94M and EPS of -$0.19.

Expected impact

Near-term volatility is likely into Aug 10, but direction is uncertain because no new guidance, results, or surprises are disclosed here.

Evidence & confidence

The newest concrete facts are the scheduled earnings date and consensus figures, plus reported institutional adds/decreases from recent quarters. There is no fresh earnings release, guidance change, or regulatory/legal event in the text.

Market effects

Sector

Limited sector read-through because the article does not include industry datapoints beyond the earnings preview.

Regional

No specific regional market linkage is provided.

Global

No global macro or cross-border catalyst is described.

Counterpoint

What could challenge this read

Fund flow changes shown here may be noisy and lagging, so they may not meaningfully predict the earnings-day reaction.

Key entities

  • company
    VIVOSIM LABS

    Subject of the earnings preview, expected to report Q1 2026 results on Aug 10 before market open.

  • data_source
    Finnhub

    Cited as the source for the expected earnings release timing.

  • data_source
    Quiver Quantitative

    Cited as the platform providing insider and institutional activity context.

Read at source← All news

Related articles

AUG 6
$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

minichart.com.sg5 min
AUG 6
$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

stocktitan.net4 min
JUL 16
$VIVSMedAI 8/10

Why Is VivoSim Labs Stock Falling Thursday? - VivoSim Labs (NASDAQ:VIVS)

VivoSim Labs (NASDAQ:VIVS) said it signed a securities purchase agreement to sell 4.71 million shares and warrants to a healthcare-focused institutional investor at an effective $0.85 per share, raising about $4.0 million gross. New warrants are exercisable at $0.85 for five years, and the company plans to amend May 2024 warrants to lower the exercise price to $0.85 and extend terms, pending approval. Shares were down 26.52% to $0.62.

benzinga.com3 min
JUL 16
$VIVSMedAI 8/10

VivoSim Labs Stock Falls 29% After Announcing $4 Mln Private Placement

VivoSim Labs (VIVS) shares fell 29.64% to $0.6001 after the company announced a $4.0 million private placement priced at $0.85 per share. VivoSim will sell about 4.71 million shares plus warrants, and will amend May 2024 warrants to reduce the exercise price to $0.85, pending shareholder approval. Net proceeds will fund working capital and general purposes.

rttnews.com3 min